Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Will Patient-Reported Data Require New Drug Labeling Framework?

Executive Summary

Whether US FDA may need to create a special labeling section for patient experience data is a ‘huge question that’s going to require a lot of discussion,’ Oncology Center of Excellence’s Kluetz says; agency is currently exploring non-labeling alternatives to communicating PRO data.

You may also be interested in...

From Listening To Advising: The Maturation Of US FDA's Patient-Focused Drug Development Program

With the disease-area meetings required under PDUFA V now behind it, FDA is turning its attention to guiding sponsors and advocacy groups on how to systematically collect patient experience data for use in drug development and regulatory decision-making. At least two guidance documents and a new data repository are on tap for 2018.

Patient Experience Data May Require Separate Label, Genentech Suggests

US labeling for Genentech's Rituxan Hycela appears to have broken new ground with a 'Patient Experience' section describing summary data from a patient preference study; however, the company's global head of outcomes research says large volumes of patient-centric data would be difficult to reflect within the current labeling framework.

Oncology Center of Excellence Open For Business: Podcast With US FDA’s Richard Pazdur

Three months after the official launch of the Oncology Center for Excellence, applications for cancer products are now being reviewed by OCE medical teams. OCE Director Richard Pazdur provides more details on the process and procedures of the newly established center in a podcast interview.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts